Literature DB >> 24518767

Partial nephrectomy in the setting of metastatic renal cell carcinoma.

Kara N Babaian1, Megan M Merrill1, Surena Matin1, Pheroze Tamboli2, Nizar M Tannir3, Eric Jonasch3, Christopher G Wood1, Jose A Karam4.   

Abstract

PURPOSE: Cytoreductive nephrectomy remains the standard of care for appropriately selected patients with metastatic renal cell carcinoma. Although the role of partial nephrectomy is well accepted in patients with localized disease, limited data are available on partial nephrectomy in the metastatic setting. We identified the indications for and outcomes of partial nephrectomy in the setting of metastatic renal cell carcinoma with particular attention to partial nephrectomy subgroups.
MATERIALS AND METHODS: We analyzed data on a consecutive cohort of 33 patients with metastatic renal cell carcinoma who underwent partial nephrectomy at a single institution between 1996 and 2011. Nonparametric statistics were used to compare partial nephrectomy subgroups. Overall survival was estimated using the Kaplan-Meier method and survival functions were compared using the log rank test.
RESULTS: At presentation 8 patients had bilateral synchronous renal masses, 20 had a metachronous contralateral renal mass and 5 had a unilateral renal mass. A total of 22 patients (67%) died of disease a median of 27 months postoperatively. Patients who underwent partial nephrectomy for a metachronous contralateral renal mass and a renal mass 4 cm or less had the best overall survival (61 and 42 months, respectively). Median overall survival in patients with vs without metastatic disease at original diagnosis was 27 vs 63 months (p = 0.003).
CONCLUSIONS: Our findings suggest that metastasis at the original diagnosis and the timing of presentation of the partial nephrectomy index lesion have an important role in survival. These factors should be considered when determining which patients would benefit from partial nephrectomy in the setting of metastatic renal cell carcinoma.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; diagnosis; kidney; neoplasm metastasis; nephrectomy; renal cell

Mesh:

Year:  2014        PMID: 24518767      PMCID: PMC4502598          DOI: 10.1016/j.juro.2014.01.086

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.

Authors:  Georg C Hutterer; Jean-Jacques Patard; Marc Colombel; Arie S Belldegrun; Christian Pfister; Francois Guille; Walter Artibani; Francesco Montorsi; Allan J Pantuck; Pierre I Karakiewicz
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

3.  Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data.

Authors:  Eirikur Guðmundsson; Henrik Hellborg; Sven Lundstam; Stina Erikson; Börje Ljungberg
Journal:  Eur Urol       Date:  2011-07-01       Impact factor: 20.096

4.  Is patient outcome compromised during the initial experience with robot-assisted radical cystectomy? Results of 164 consecutive cases.

Authors:  Matthew H Hayn; Nicholas J Hellenthal; Stéfanie A Seixas-Mikelus; Ahmed M Mansour; Andrew Stegemann; Abid Hussain; Khurshid A Guru
Journal:  BJU Int       Date:  2010-12-16       Impact factor: 5.588

5.  Metastatic potential of a renal mass according to original tumour size at presentation.

Authors:  Eric C Umbreit; Mark S Shimko; M Adam Childs; Christine M Lohse; John C Cheville; Bradley C Leibovich; Michael L Blute; R Houston Thompson
Journal:  BJU Int       Date:  2011-05-09       Impact factor: 5.588

6.  Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.

Authors:  Ken-Ryu Han; Allan J Pantuck; Matthew H T Bui; Oleg Shvarts; Danielo G Freitas; Amnon Zisman; Bradley C Leibovich; Frederick J Dorey; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

7.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

Authors:  M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz
Journal:  Ann Oncol       Date:  2011-09-02       Impact factor: 32.976

8.  Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.

Authors:  Tobias Klatte; Jean-Jacques Patard; Michela de Martino; Karim Bensalah; Gregory Verhoest; Alexandre de la Taille; Clément-Claude Abbou; Ernst Peter Allhoff; Giuseppe Carrieri; Stephen B Riggs; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  J Urol       Date:  2008-03-17       Impact factor: 7.450

9.  Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.

Authors:  Umberto Capitanio; Laurent Zini; Paul Perrotte; Shahrokh F Shariat; Claudio Jeldres; Philippe Arjane; Daniel Pharand; Hugues Widmer; François Péloquin; Francesco Montorsi; Jean-Jacques Patard; Pierre I Karakiewicz
Journal:  Urology       Date:  2008-09-16       Impact factor: 2.649

10.  The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.

Authors:  Stephen A Boorjian; Paul L Crispen; Christine M Lohse; Bradley C Leibovich; Michael L Blute
Journal:  Eur Urol       Date:  2008-05-09       Impact factor: 20.096

View more
  3 in total

Review 1.  New challenges in kidney cancer management: integration of surgery and novel therapies.

Authors:  Javier Puente Vázquez; T Alonso Gordoa; J Moreno; L Poma; E Diaz Rubio; A Gomez; J Blazquez; J L Gonzalez Larriba
Journal:  Curr Treat Options Oncol       Date:  2015-03

2.  Key genes associated with prognosis and metastasis of clear cell renal cell carcinoma.

Authors:  Tingting Zhong; Zeying Jiang; Xiangdong Wang; Honglei Wang; Meiyi Song; Wenfang Chen; Shicong Yang
Journal:  PeerJ       Date:  2022-01-04       Impact factor: 2.984

3.  Outlining the limits of partial nephrectomy.

Authors:  Sameer Chopra; Raj Satkunasivam; Chandan Kundavaram; Gangning Liang; Inderbir S Gill
Journal:  Transl Androl Urol       Date:  2015-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.